by Peter Ciszewski | Feb 7, 2019
The U.S. Food and Drug Administration (FDA) approved Cablivi (caplacizumab-yhdp) injection, the first therapy specifically indicated, in combination with plasma exchange and immunosuppressive therapy, for the treatment of adult patients with acquired thrombotic...
by Peter Ciszewski | Feb 6, 2019
Daniel MacArthur, PhD is an Institute Member at the Broad Institute of MIT and Harvard, and co-lead of the Broad’s Center for Mendelian Genomics and Rare Genomes Project. Dr. MacArthur is a group leader in the Analytic and Translational Genetics Unit at...
by Peter Ciszewski | Feb 5, 2019
Pushkal Garg, MD, Chief Medical Officer at Alnylam discusses hereditary ATTR (hATTR) amyloidosis, a rare condition that affects an estimated 50,000 people worldwide. Symptoms can affect multiple parts of the body, including the nervous (nerve), cardiac (heart),...
by Peter Ciszewski | Feb 4, 2019
Other Names: aHUS; Atypical HUS; HUS, atypical Atypical hemolytic uremic syndrome (aHUS) is a disease that causes abnormal blood clots to form in small blood vessels in the kidneys. These clots can cause serious medical problems if they restrict or block blood flow,...
by Peter Ciszewski | Jan 31, 2019
By Peter Ciszewski; January 3, 2019 Mitchell Cairo, MD, Chief of Pediatric Hematology, Oncology and Stem Cell Transplantation at New York Medical College discusses his study at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego. Sickle cell...
